Index

A
ACPAs. See Antibodies to citrullinated peptide antigens
Activation-induced cell death (AICD), 25
AICD. See Activation-induced cell death
AIRE, 3, 18–19, 24, 88, 103–104
AKT, 35
Alefacept, 136
ALPS. See Autoimmune lymphoproliferative syndrome
ALS. See Antilymphocyte serum
Altered peptide ligands (APLs), tolerance restoration in autoimmunity, 134–135
AMPK, 23
Anergy
B cell, 56
t-cell peripheral tolerance, 23–24
Anti-CD3. See OKT3
Antibodies to citrullinated peptide antigens (ACPAs), 91
Antigen-presenting cell (APC). See also specific cells
history of study, 4
t cell
central tolerance
dendritic cell, 19, 51
medullary thymic epithelial cell, 18–19
peripheral tolerance, 24–25
therapeutic targeting in autoimmune disease, 137
tolerogenic cells, 24–25
Antilymphocyte serum (ALS), tolerance restoration in autoimmunity, 130
Antithymocyte globulin (ATG), tolerance restoration in autoimmunity, 130
APC. See Antigen-presenting cell
APECED. See Autoimmune polyendocrinopathy candidiasis ectodermal dys trophy
APLs. See Altered peptide ligands
APS-1. See Autoimmune polyendocrine syndrome type 1
ATG. See Antithymocyte globulin
Autoimmune lymphoproliferative syndrome (ALPS), 87
Autoimmune polyendocrine syndrome type 1 (APS-1), 87, 93
Autoimmune polyendocrinopathy candidiasis ectodermal dys trophy syndrome (APECED), 18, 93, 127
Autoimmunity. See also specific diseases
commensal microbiota effects
microbial lineage effects, 106–108
overview, 103–105
promotion mechanisms, 105–106
protective effects, 108–109
commensalism establishment
legume–rhizobia symbiosis, 116–117
mammalian conserved signals, 118–119
nematode–Xenorhabdus symbiosis, 118
squid–Vibrio fischeri symbiosis, 117–118
environmental influences, 103–105
genetics
architecture, 89–91
clinical application, 91
hidden genetic risk, 94–96
human leukocyte antigen haplotypes, 91–92
polymorphisms
common risk variants, 92–93
disease-specific risk variants, 93–94
prospects for study, 96–97
strategies for gene identification, 88–89
history of study, 7–9
human gene mutations in microbial recognition, 119–120
immunotolerance study prospects, 122–123
infectious inflammation as frustrated commensalism, 120–122
tolerance restoration through immunomodulation
antigen-specific immunotherapy, 133–136
cellular therapies, 138–141
prospects, 141
systemic immunotherapy, 130–133
t-cell costimulation targeting, 136–138
targets, 128–130
B
BAFF, 68–69
B cell
anergy, 5–6
autoimmune disease therapeutic targeting, 133
central tolerance
clonal deletion, 61
cytokines, 68–69
low-avidity interactions, 65
overview, 59–61
positive selection of immature B cells, 66–68
prospects for study, 69–70
receptor editing
hazards, 65–66
overview, 61–62
tolerance role, 63–65

© 2013 by Cold Spring Harbor Laboratory Press
Index

B-cell receptor (BCR)
  B-cell anergy role, 5
eediting
  hazards, 65–66
  overview, 61–62
  tolerance role, 63–65
  history of central tolerance studies, 2
  signaling in immature cells, 66–68
  Bcl-2, 67
  BCR. See B-cell receptor
  BIM, 20, 25
  Blimp-1, 53

C
  CARMA1, 35
  CD5, 3
  CD40, therapeutic targeting in autoimmune disease, 137
  CD154, therapeutic targeting in autoimmune disease, 137
  Central tolerance
    clonal deletion, 61
    cytokines, 68–69
    low-avidity interactions, 65
    overview, 59–61
    positive selection of immature B cells, 66–68
    prospects for study, 69–70
    receptor editing
      hazards, 65–66
      overview, 61–62
      tolerance role, 63–65
    history of study, 2–3
  T cell
    antigen-presenting cells
      dendritic cell, 19
      medullary thymic epithelial cell, 18–19
    clonal deletion
      clonal diversion distinction, 22–23
      mechanisms, 19–21
      stages, 16–18
      clonal diversion, 21–23
    overview, 15–16
  Chronic inflammatory demyelinating polyneuropathy (CIDP), 133
  CIDP. See Chronic inflammatory demyelinating polyneuropathy
  Clonal deletion
    B-cell central tolerance, 61
    T cell
      clonal diversion distinction, 22–23
      mechanisms, 19–21
      stages, 16–18
  Clonal diversion, T cell, 21–23
  Cohn, Zanvil, 45
  Commensal microbiota
    autoimmunity effects
    microbial lineage effects, 106–108
    overview, 103–105
    promotion mechanisms, 105–106
    protective effects, 108–109
    health maintenance overview, 101–102
  Costimulation
    anergy, 23–24
    history of study, 4–6
    T-cell clonal deletion, 21
    targeting in autoimmune disease treatment, 136–138
  Crohn’s disease, 53, 89, 91, 137–138
  CTLA-4, 89
    autoimmunity polymorphisms, 8
    costimulation, 5, 25
    dominant tolerance role, 4
    T-cell anergy role, 24
    tolerance restoration therapies in autoimmunity, 130, 136
  DAMPs. See Danger-associated molecular patterns
  Danger-associated molecular patterns (DAMPs), 5
  DC. See Dendritic cell
  DCLRE1C, autoimmune disease polymorphisms, 92
  Dendritic cell (DC)
    history of study, 45–46
    lineage, 46–47
    pathogens in subversion, 50–51
    peripheral tolerance studies
      cell loss impact, 52
      intrinsic breach of immune tolerance, 52–52
      regulatory T-cell homeostasis, 53–54
      self-antigen presentation, 51–52
    prospects for study, 34
    subsets
      heterogeneity, 46–47
      humans, 48–49
      tolerance implications, 49–50
    targeting in autoimmune disease treatment, 140
    T-cell interactions
      central tolerance role, 19, 51
      peripheral tolerance role, 24–25
      response initiation, 50
  Diabetes type 1
    islet destruction mechanisms, 8–9
    susceptibility loci, 7–8, 90
    tolerance restoration in autoimmunity, 132, 134–136, 139–140
  Dominant tolerance, history of study, 3–4
  Efalizumab, 137
  ERK. See Extracellular signal-regulated kinase
  Extracellular signal-regulated kinase (ERK), 20

© 2013 by Cold Spring Harbor Laboratory Press
F
Fas
mutation in autoimmunity, 88
T-cell peripheral deletion role, 25
Fingolimod, 137
Flt3 L, 53
FoxP3, 21, 31, 88, 104
FoxP3+CD4+ T cell. See Regulatory T cell
FTY720, 138

G
GAD65, 135
Genome-wide association study (GWAS),
autoimmunity genes, 89, 94
Graft versus host disease (GVHD), 140
Guillain–Barré syndrome, 133
GVHD. See Graft versus host disease
GWAS. See Genome-wide association study

H
HEL, 65
Hematopoietic stem cell transplantation (HSCT),
autoimmune disease treatment, 138–139
HIV. See Human immunodeficiency virus
HSCT. See Hematopoietic stem cell transplantation
Human immunodeficiency virus (HIV), 113
Human leukocyte antigen. See Major histocompatibility complex

I
IL-2. See Interleukin-2
IL2RA, autoimmune disease polymorphisms, 93
IL-7. See Interleukin-7
IL7RA, autoimmune disease polymorphisms, 92
IL23R, autoimmune disease polymorphisms, 93
Immunodysregulation, polyendocrinopathy, and enteropathy X-linked syndrome (IPEX),
eighty seven, ninety three, one hundred four, one hundred twenty seven
Inflammation
infectious inflammation as frustrated commensalism, one hundred twenty
 targeting in autoimmune disease treatment, one hundred thirty six–one hundred thirty eight
Interleukin-2 (IL-2)
autoimmunity role, nine
dominant tolerance role, four
tolerance restoration in autoimmunity, one hundred thirty two
Treg induction, thirty four
Interleukin-7 (IL-7), sixty eight
Intravenous immunoglobulin (IVIG), tolerance restoration in autoimmunity, one hundred thirty three
IPEX. See Immunodysregulation, polyendocrinopathy, and enteropathy X-linked syndrome
IRAK4, one hundred nineteen
Irf4, thirty seven–thirty eight
IVIG. See Intravenous immunoglobulin

K
KAZALD1, autoimmune disease polymorphisms, ninety four

L
Langerhans, Paul, forty five
LCMV. See Lymphocytic choriomeningitis virus
Listeria, dendritic cell subversion, fifty one
LNSC. See Lymph node stromal cell
Lymph node stromal cell (LNSC), T-cell peripheral tolerance role, twenty four–twenty five
Lymphocyte choriomeningitis virus (LCMV), one hundred five

M
Major histocompatibility complex (MHC)
autoimmune disease human leukocyte antigen haplotypes, ninety one–ninety two
class II molecules in tolerance restoration in autoimmunity, one hundred thirty three–one hundred thirty four
diabetes type 1 susceptibility loci, seven
natural killer cell tolerance and class I molecules
MHC-I-independent tolerance mechanisms, seventy nine–eighty two
role, seventy six, seventy nine
Mammalian target of rapamycin (mTOR), twenty three
MBP. See Myelin basic protein
Medullary thymic epithelial cell (mTEC), T-cell central tolerance role, eighteen–nineteen, one hundred twenty nine
Mesenchymal stem cell (MSC), autoimmune disease treatment, one hundred thirty nine
MHC. See Major histocompatibility complex
Microbial-associated molecular patterns. See Pathogen-associated molecular patterns
Microbiota. See Commensal microbiota
MS. See Multiple sclerosis
MSC. See Mesenchymal stem cell
mTEC. See Medullary thymic epithelial cell
mTOR. See Mammalian target of rapamycin
Multiple sclerosis (MS)
genetics, eighty eight–eighty nine, ninety two
therapeutic targets, one hundred thirty three–one hundred forty
MyD88, one hundred nineteen
Myelin basic protein (MBP), one hundred thirty four–one hundred thirty five

N
Natural killer (NK) cell
functional overview, seventy five–seventy six
invariant cells, one hundred two
major histocompatibility complex class I molecules
Natural killer (NK) cell (Continued.)
MHC-I-independent tolerance mechanisms, 79–82
tolerance role, 76, 79
reactivity analysis models, 77–78
tolerance
breaking, 83
maintenance, 82–83
prospects for study, 83
NF-κB. See Nuclear factor-κB
Nitric oxide synthase (NOS), 117, 122
NK cell. See Natural killer cell
NKG2D, 75, 82
NOS. See Nitric oxide synthase
Nuclear factor-κB (NF-κB), 4, 35
NUR77, 20, 35
OKT3, tolerance restoration in autoimmunity, 131
Owen, Ray, 2
P
PAMPs. See Pathogen-associated molecular patterns
Pathogen-associated molecular patterns (PAMPs), 4, 103, 115–117, 120, 122
Pattern recognition receptors (PRRs), 114–116, 119–120
PD-1, 24
Peripheral tolerance, T cell
anergy, 23–24
antigen-presenting cells, 24–25
dendritic cell studies
cell loss impact, 52
intrinsic breach of immune tolerance, 52–52
regulatory T-cell homeostasis, 53–54
self-antigen presentation, 51–52
overview, 23
peripheral deletion, 25
Plasmacytoid dendritic cell (pDC), 46, 50
PRRs. See Pattern recognition receptors
PTPN22, autoimmune disease polymorphisms, 89, 91, 93–94
RA. See Rheumatoid arthritis
RAG1, autoimmune disease polymorphisms, 92
Rapamycin, T-cell anergy induction, 23
Regulatory T cell (Treg)
dendritic cell in homeostasis, 53–54
differentiation, 32–35
diversity, 37–38
effector strategies, 37
functional overview, 31–32
history of study
dominant tolerance, 3–4
immunoregulation, 6–7
intravenous immunoglobulin effects, 133
iTreg, 6
location and migration, 36–37
phenotypic stability, 35–36
pTreg, 33–34
T-cell receptor repertoire, 36
therapeutic targeting in autoimmunity, 140–141
Treg, 6
Rheumatoid arthritis (RA), 94, 133, 136
Rhizobia. See Commensal microbiota
Rituximab, tolerance restoration in autoimmunity, 133
RMRP, autoimmune disease polymorphisms, 92
S
SLE. See Systemic lupus erythematosus
Steinman, Ralph, 45
Symbiosis. See Commensal microbiota
Systemic lupus erythematosus (SLE), 6, 8, 92
T
TAK1, 35
Tbet, 37
T cell. See also specific T cells
central tolerance
antigen-presenting cells
dendritic cell, 19, 51
medullary thymic epithelial cell, 18–19
clonal deletion
clonal diversion distinction, 22–23
mechanisms, 19–21
stages, 16–18
clonal diversion, 21–23
overview, 15–16
peripheral tolerance
anergy, 23–24
antigen-presenting cells, 24–25
dendritic cell studies
cell loss impact, 52
intrinsic breach of immune tolerance, 52–52
regulatory T-cell homeostasis, 53–54
self-antigen presentation, 51–52
overview, 23
peripheral deletion, 25
therapeutic targeting in autoimmune disease, 129–130
T-cell receptor (TCR)
activation, 5
clonal diversion, 21
costimulation, 21
Index

history of central tolerance studies, 2–3
transgenic mice, 140–141
Treg, 34–36
TCR. See T-cell receptor
T helper (Th) cell
effectors, 31
pathogen specificity, 6
Th17, 35, 37–38
TGF-β. See Transforming growth factor-β
Th cell. See T helper cell
TLRs. See Toll-like receptors
TNF-α. See Tumor necrosis factor-α
Tolerance. See Autoimmunity; Central tolerance;
Dominant tolerance; Peripheral tolerance
Toll-like receptors (TLRs), 4, 8, 115, 119
Toxoplasma, dendritic cell subversion, 50
TRAF3, 119
TRAF6, 19
Transforming growth factor-β (TGF-β)
clonal diversion role, 22
dominant tolerance role, 4
regulatory T cell
induction, 34
secretion, 36
therapeutic targeting in autoimmune disease, 130
Treg. See Regulatory T cell
Tuberculosis, 113, 121–122
Tumor necrosis factor-α (TNF-α), targeting in auto-
immune disease treatment, 136, 138

U
UNC93B, 119

V
V(D)J recombination, 62–63, 67
Vibrio fischeri. See Commensal microbiota

X
Xenorhabdus. See Commensal microbiota

© 2013 by Cold Spring Harbor Laboratory Press